Related Experiment Video
Updated: Mar 24, 2026
08:36
Measuring Dengue Virus RNA in the Culture Supernatant of Infected Cells by Real-time Quantitative Polymerase Chain Reaction
Published on: November 1, 2018
32.7K
Vaccine Development as a Means to Control Dengue Virus Pathogenesis: Do We Know Enough?
Theodore C Pierson1, Michael S Diamond2
1Viral Pathogenesis Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892;
Annual Review of Virology
|March 10, 2016
Summary
Developing a dengue virus (DENV) vaccine is challenging due to four serotypes and secondary infection risks. This review explores promising DENV vaccine candidates and recent biological insights for effective vaccine development.
Area of Science:
- * Virology
- * Immunology
- * Vaccinology
Background:
- * Dengue virus (DENV) causes significant global morbidity and mortality.
- * 70 years of research have yielded limited success in DENV vaccine development.
- * Challenges include protecting against four serotypes and understanding secondary infection pathogenesis.
Purpose of the Study:
- * To review promising dengue virus vaccine candidates in clinical trials.
- * To assess how recent advances in DENV biology and immunity can aid vaccine development.
Main Methods:
- * Literature review of DENV vaccine research.
- * Analysis of current clinical trial data for DENV vaccines.
- * Synthesis of recent findings in DENV virology and immunology.
Main Results:
- * Several DENV vaccine candidates show promise in clinical trials.
- * Advances in understanding DENV biology offer new avenues for vaccine design.
- * Improved knowledge of DENV immunity is crucial for efficacy.
Conclusions:
- * Continued research into DENV biology and immunity is essential.
- * Promising vaccine candidates may overcome historical challenges.
- * Development of safe and effective DENV vaccines is achievable.
